PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Antzeko izenburuak

• PTPN9 IS A NEGATIVE REGULATOR OF HER3 PHOSPHORYLATION AND A PROGNOSTIC BIOMARKER IN HER2 POSITIVE BREAST CANCER
  nork: Gijsen, M, et al.
  Argitaratua: (2012)
• Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
  nork: Negar Pourjamal, et al.
  Argitaratua: (2025-03-01)
• Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
  nork: Baubek Spanov, et al.
  Argitaratua: (2022-01-01)
• Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
  nork: Arshad, M, et al.
  Argitaratua: (2024)
• Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
  nork: Alena Rudkouskaya, et al.
  Argitaratua: (2020-12-01)